The study and its comparison
A randomized controlled trial enrolled 613 participants. Its population was patients with mild to moderate alzheimer disease taking an acetylcholinesterase inhibitor. The comparison used alpha tocopherol 2000 iu daily, memantine, their combination or placebo, with observation over mean follow-up 2.27 years. [1]
Among 561 participants with follow-up, daily-living scores declined 3.15 points less with vitamin E than placebo. Neither memantine alone nor the combination showed a significant advantage on this comparison. [1]
What the finding establishes
Fifty-two randomized participants had no follow-up data. The high research amount and background medication are essential context, not instructions for self-treatment. The primary endpoint concerned daily activities rather than a cure or proven memory restoration. Combining interventions did not reproduce the vitamin-E-only finding. Funding and complete conflicts were not established from the retrieved abstract. [1]
A hypothetical distinction
Imagine daily activities deteriorate more slowly while disease remains present. That supports a narrower claim than reversing the disease.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.